News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co. (MRK) Announces Completion Of Acquisition Of Aton Pharma, Inc. And Sale Of 50 Percent Equity Stake In Johnson & Johnson.MSD Europe


10/19/2005 5:10:37 PM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--March 30, 2004--Merck & Co., Inc. today announced that it has successfully completed the acquisition of Aton Pharma, Inc. and the sale of Merck's 50 percent equity stake in Johnson & Johnson*MSD Europe to Johnson & Johnson, both of which closed in the first quarter of 2004.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical products company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.

Merck Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q and Form 8-K (if any) which we incorporate by reference. Copies of these forms are available on request to Merck's Office of Stockholder Services.

Contacts

Merck & Co., Inc. Media Contact: Janet Skidmore, 908/423-3046 Investor Contact: Mark Stejbach, 908/423-5185


Read at Reuters
Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES